Related Experiment Videos
A rapid and efficient system for screening HIV-1 Pol mRNA-specific ribozymes
A Ramezani1, W Marhin, M Weerasinghe
1Department of Medical Genetics and Microbiology, University of Toronto, ON, Canada.
Canadian Journal of Microbiology
|January 1, 1997
Summary
Hammerhead ribozymes show promise for gene therapy by targeting unwanted RNAs. This study developed a system to test ribozymes against human immunodeficiency virus type-1 (HIV-1) polymerase mRNA, with one ribozyme significantly reducing viral activity in vivo.
Area of Science:
- Molecular Biology
- Biotechnology
- Antiviral Therapy
Background:
- Hammerhead ribozymes are RNA molecules with catalytic activity, capable of cleaving specific RNA sequences.
- Their application in suppressing intracellular gene expression, particularly for therapeutic purposes like combating viral infections, has shown variable success.
- Developing efficient in vivo testing systems is crucial for advancing ribozyme-based therapies.
Purpose of the Study:
- To establish a rapid and effective in vivo system for testing the efficacy of hammerhead ribozymes against human immunodeficiency virus type-1 (HIV-1) polymerase mRNA.
- To evaluate two specific ribozymes, RzPro and RzRT, targeting the protease and reverse transcriptase coding regions of HIV-1 polymerase mRNA, respectively.
- To assess the impact of ribozyme activity on HIV-1 reverse transcriptase (RT) enzyme activity in vivo.
Main Methods:
- Design and in vitro testing of two HIV-1 polymerase mRNA-specific ribozymes (RzPro and RzRT) in Escherichia coli.
- Adaptation of RNA polymerase chain reaction (PCR) to confirm in vivo cleavage of target RNA sequences.
- Measurement of the reduction in HIV-1 RT activity in cells expressing the designed ribozymes.
Main Results:
- Both RzPro and RzRT demonstrated comparable RNA cleavage efficiencies in vitro.
- In vivo cleavage of target sites by both ribozymes was confirmed using RNA PCR.
- Cells expressing RzRT exhibited a significant reduction in HIV-1 RT activity, decreasing by up to 96%.
Conclusions:
- The developed system enables rapid in vivo screening of ribozymes against HIV-1 polymerase mRNA.
- This platform can facilitate the design of multi-targeted ribozymes for anti-HIV-1 gene therapy.
- The system aids in identifying ribozymes with enhanced stability, catalytic activity, and potential cofactor requirements for improved in vivo performance.